Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Ghez

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Plos One|April 12, 2008
Phenotypic and genotypic characteristics of mastocytosis according to the age of onsetFanny Lanternier, Annick Cohen-Akenine, Fabienne Palmerini, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
American Journal of Hematology|June 24, 2021
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 studyClémentine Sarkozy, Jean-Marie Michot, Cyril Quivoron, et al.
American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.
Frontiers in Immunology|November 3, 2023
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infectionDéborah Lécuyer, Roberta Nardacci, Désirée Tannous, et al.
Blood|September 22, 2020
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19Thomas Hueso, Cécile Pouderoux, Hélène Péré, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Investigational New Drugs|June 10, 2017
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trialsJean-Marie Michot, Lina Benajiba, Laura Faivre, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Plos One|April 12, 2008
Phenotypic and genotypic characteristics of mastocytosis according to the age of onsetFanny Lanternier, Annick Cohen-Akenine, Fabienne Palmerini, et al.
Haematologica|December 22, 2022
Retrospective analysis of a cohort of 41 <i>de novo</i> B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study)Caroline Algrin, Louis Pérol, Elise Chapiro, et al.
American Journal of Hematology|June 24, 2021
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 studyClémentine Sarkozy, Jean-Marie Michot, Cyril Quivoron, et al.
American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.
Frontiers in Immunology|November 3, 2023
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infectionDéborah Lécuyer, Roberta Nardacci, Désirée Tannous, et al.
Blood|September 22, 2020
Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19Thomas Hueso, Cécile Pouderoux, Hélène Péré, et al.
Pageof 8